[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
February 7, 2007

Incorrect Funding Listed in: Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial

JAMA. 2007;297(5):470. doi:10.1001/jama.297.5.470-a

Incorrect Funding Listed: In the Original Contribution entitled “Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial” published in the May 21, 2003, issue of JAMA (2003;289:2525-2533), Wyeth-Ayerst Laboratories did not provide Os-Cal Plus D. On page 2532, under Funding/Support, the last sentence should read “Wyeth-Ayerst Laboratories (Philadelphia, Pa) provided the Premarin and Prempro, matching placebo, and Caltrate Plus D, and Merck Research Laboratories (Rahway, NJ) provided the alendronate and matching placebo used in this study.”

×